Loading...
Market
Which region will grant the next major regulatory approval for Winrevair by December 31, 2024?
2
Resolution / Starting Odds
European Union • 25%
Japan • 25%
Canada • 25%
Other • 25%
Official announcements from respective regulatory bodies or Merck press release
Story
Merck's Winrevair Shows Positive Results in Phase 3 Trial, Reducing Risk of Death
Nov 25, 2024, 12:00 PM
Merck announced on Monday that its drug, Winrevair (sotatercept-csrk), has shown significant results in reducing the risk of death in patients with a rare lung condition that causes high blood pressure. The announcement follows the Pivotal Phase 3 ZENITH Trial, which met its primary endpoint at an interim analysis. This development comes months after the drug secured approval in the United States.
View original story
Similar markets
European Union • 25%
United Kingdom • 25%
Australia • 25%
Other • 25%
United States • 25%
United Kingdom • 25%
Australia • 25%
Other • 25%
Yes • 50%
No • 50%
European Medicines Agency (EMA) • 25%
Health Canada • 25%
Japan's PMDA • 25%
Other • 25%
United States • 25%
United Kingdom • 25%
European Union • 25%
Other • 25%
Yes • 50%
No • 50%
Japan • 25%
Canada • 25%
Australia • 25%
None of the above • 25%
Yes • 50%
No • 50%
United States • 25%
European Union • 25%
China • 25%
Other • 25%
European Union • 25%
Canada • 25%
Japan • 25%
Other • 25%
United States • 25%
European Union • 25%
China • 25%
Other • 25%